Cargando…

A Tertiary Care Centre Experience of Recurrent Giant Cell Tumor Around the Knee Joint

Introduction: Giant cell tumor (GCT) is a benign but locally aggressive bone tumor. It has a peak incidence between 30-40 years with a predilection for the epiphyseal/metaphyseal region of bone. The most common locations for bone GCT are the distal femur, proximal tibia, distal radius, and sacrum in...

Descripción completa

Detalles Bibliográficos
Autores principales: Behera, Kshitish C, Singla, Mohit, Yadav, Umesh, KP, Majumdar, Shukla, Tapish, Gupta, Anand, Sheoran, Ajay, Kundu, Zile Singh, Devgun, Ashish, Paul, Shagnik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618282/
https://www.ncbi.nlm.nih.gov/pubmed/36340544
http://dx.doi.org/10.7759/cureus.29788
_version_ 1784821015831904256
author Behera, Kshitish C
Singla, Mohit
Yadav, Umesh
KP, Majumdar
Shukla, Tapish
Gupta, Anand
Sheoran, Ajay
Kundu, Zile Singh
Devgun, Ashish
Paul, Shagnik
author_facet Behera, Kshitish C
Singla, Mohit
Yadav, Umesh
KP, Majumdar
Shukla, Tapish
Gupta, Anand
Sheoran, Ajay
Kundu, Zile Singh
Devgun, Ashish
Paul, Shagnik
author_sort Behera, Kshitish C
collection PubMed
description Introduction: Giant cell tumor (GCT) is a benign but locally aggressive bone tumor. It has a peak incidence between 30-40 years with a predilection for the epiphyseal/metaphyseal region of bone. The most common locations for bone GCT are the distal femur, proximal tibia, distal radius, and sacrum in decreasing order. Material and Methods: In this retrospective study, 22 patients (13 females and nine males) with recurrent giant cell tumors around the knee joint between 2009-2022, with a mean age of 30.2 years (range: 18-55) were included. The patients were followed up monthly for three months, three-monthly for the next two years, six-monthly for the next five years, and thereafter, yearly. The mean follow-up period was 36.97 months (range 23-120 months). Results: There were 19 recurrences after curettages and three after resections. Re-extended curettage was done in 17 cases and the resultant cavities were filled with autologous bone grafts in six and with polymethyl methacrylate (PMMA) cement in the other 11 cases. Reconstruction with megaprosthesis was done in two patients whereas knee arthrodesis was done in two patients after wide resection. The average Musculoskeletal Tumor Society (MSTS) score of our series of 22 patients was 23.1 (Range: 19-30). Conclusion: Campanacci grade 1 and 2 lesions can be successfully treated with extended curettage and bone grafting/bone cementing. For patients with grade 3 lesions, there are two options available according to the financial status of the patient; the first option is reconstruction with prosthesis and the other option is arthrodesis.
format Online
Article
Text
id pubmed-9618282
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-96182822022-11-03 A Tertiary Care Centre Experience of Recurrent Giant Cell Tumor Around the Knee Joint Behera, Kshitish C Singla, Mohit Yadav, Umesh KP, Majumdar Shukla, Tapish Gupta, Anand Sheoran, Ajay Kundu, Zile Singh Devgun, Ashish Paul, Shagnik Cureus Orthopedics Introduction: Giant cell tumor (GCT) is a benign but locally aggressive bone tumor. It has a peak incidence between 30-40 years with a predilection for the epiphyseal/metaphyseal region of bone. The most common locations for bone GCT are the distal femur, proximal tibia, distal radius, and sacrum in decreasing order. Material and Methods: In this retrospective study, 22 patients (13 females and nine males) with recurrent giant cell tumors around the knee joint between 2009-2022, with a mean age of 30.2 years (range: 18-55) were included. The patients were followed up monthly for three months, three-monthly for the next two years, six-monthly for the next five years, and thereafter, yearly. The mean follow-up period was 36.97 months (range 23-120 months). Results: There were 19 recurrences after curettages and three after resections. Re-extended curettage was done in 17 cases and the resultant cavities were filled with autologous bone grafts in six and with polymethyl methacrylate (PMMA) cement in the other 11 cases. Reconstruction with megaprosthesis was done in two patients whereas knee arthrodesis was done in two patients after wide resection. The average Musculoskeletal Tumor Society (MSTS) score of our series of 22 patients was 23.1 (Range: 19-30). Conclusion: Campanacci grade 1 and 2 lesions can be successfully treated with extended curettage and bone grafting/bone cementing. For patients with grade 3 lesions, there are two options available according to the financial status of the patient; the first option is reconstruction with prosthesis and the other option is arthrodesis. Cureus 2022-09-30 /pmc/articles/PMC9618282/ /pubmed/36340544 http://dx.doi.org/10.7759/cureus.29788 Text en Copyright © 2022, Behera et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Orthopedics
Behera, Kshitish C
Singla, Mohit
Yadav, Umesh
KP, Majumdar
Shukla, Tapish
Gupta, Anand
Sheoran, Ajay
Kundu, Zile Singh
Devgun, Ashish
Paul, Shagnik
A Tertiary Care Centre Experience of Recurrent Giant Cell Tumor Around the Knee Joint
title A Tertiary Care Centre Experience of Recurrent Giant Cell Tumor Around the Knee Joint
title_full A Tertiary Care Centre Experience of Recurrent Giant Cell Tumor Around the Knee Joint
title_fullStr A Tertiary Care Centre Experience of Recurrent Giant Cell Tumor Around the Knee Joint
title_full_unstemmed A Tertiary Care Centre Experience of Recurrent Giant Cell Tumor Around the Knee Joint
title_short A Tertiary Care Centre Experience of Recurrent Giant Cell Tumor Around the Knee Joint
title_sort tertiary care centre experience of recurrent giant cell tumor around the knee joint
topic Orthopedics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618282/
https://www.ncbi.nlm.nih.gov/pubmed/36340544
http://dx.doi.org/10.7759/cureus.29788
work_keys_str_mv AT beherakshitishc atertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT singlamohit atertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT yadavumesh atertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT kpmajumdar atertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT shuklatapish atertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT guptaanand atertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT sheoranajay atertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT kunduzilesingh atertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT devgunashish atertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT paulshagnik atertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT beherakshitishc tertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT singlamohit tertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT yadavumesh tertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT kpmajumdar tertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT shuklatapish tertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT guptaanand tertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT sheoranajay tertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT kunduzilesingh tertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT devgunashish tertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint
AT paulshagnik tertiarycarecentreexperienceofrecurrentgiantcelltumoraroundthekneejoint